Anti-CCL21 Antibody Attenuates Infarct Size and Improves Cardiac Remodeling After Myocardial Infarction | Zendy

Yi Jiang | Zendy; Jianwen Bai | Zendy; Lunxian Tang | Zendy; Pei Zhang | Zendy; Jun Pu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-CCL21 Antibody Attenuates Infarct Size and Improves Cardiac Remodeling After Myocardial Infarction

Author(s) -

Yi Jiang,

Jianwen Bai,

Lunxian Tang,

Pei Zhang,

Jun Pu

Publication year - 2015

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000430224

Subject(s) - medicine , myocardial infarction , ccl21 , cardiology , inflammation , ventricular remodeling , chemokine , cardiac function curve , monocyte , immune system , immunology , chemokine receptor , heart failure

Over-activation of cellular inflammatory effectors adversely affects myocardial function after acute myocardial infarction (AMI). The CC-chemokine CCL21 is, via its receptor CCR7, one of the key regulators of inflammation and immune cell recruitment, participates in various inflammatory disorders, including cardiovascular ones. This study explored the therapeutic effect of an anti-CCL21 antibody in cardiac remodeling after myocardial infarction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research